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Abstract
Purpose HFpEF (heart failure with preserved ejection fraction) is a major consequence of diabetic cardiomyopathy with no
effective treatments. Here, we have characterized Akita mice as a preclinical model of HFpEF and used it to confirm the
therapeutic efficacy of the mitochondria-targeted dicarbonyl scavenger, MitoGamide.
Methods and Results A longitudinal echocardiographic analysis confirmed that Akita mice develop diastolic dysfunction with
reduced E peak velocity, E/A ratio and extended isovolumetric relaxation time (IVRT), while the systolic function remains
comparable with wild-type mice. The myocardium of Akita mice had a decreased ATP/ADP ratio, elevated mitochondrial
oxidative stress and increased organelle density, compared with that of wild-type mice. MitoGamide, a mitochondria-targeted
1,2-dicarbonyl scavenger, exhibited good stability in vivo, uptake into cells and mitochondria and reactivity with dicarbonyls.
Treatment of Akita mice with MitoGamide for 12 weeks significantly improved the E/A ratio compared with the vehicle-treated
group.
Conclusion Our work confirms that the Akita mouse model of diabetes replicates key clinical features of diabetic HFpEF,
including cardiac and mitochondrial dysfunction. Furthermore, in this independent study, MitoGamide treatment improved
diastolic function in Akita mice.
Keywords Diabetes . Heart failure with preserved ejection fraction (HFpEF) . Akita mice . Advanced glycation endproducts
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Introduction
Heart failure with preserved ejection fraction (HFpEF) is an
early cardiac manifestation found in young diabetic individ-
uals, whereas heart failure with reduced ejection fraction
(HFrEF) develops predominantly in older age groups [1].
Despite the prevalence of HFpEF among diabetic patients,
the underlying pathophysiological mechanisms are unclear,
limiting the development of rational therapies. Indeed, cur-
rently available anti-diabetic drugs are of limited efficacy
against both HFpEF and HFrEF, and the associated increase
in mortality [2]. Hence, there is a clear unmet need to more
effectively target cardiac damage in diabetes to protect against
heart failure. A major impediment to developing drugs for
HFpEF is the lack of preclinical animal models that closely
replicate the human pathology.
The glucose elevation associated with diabetes increases
formation of reactive 1,2-dicarbonyls, such as methylglyoxal
and glyoxal, with elevated levels in diabetic patients [3].
Methylglyoxal and glyoxal are a major cause of the accumu-
lation of protein glycation and of advanced glycation
endproducts (AGEs) in diabetes [4]. These modifications are
thought to disrupt protein function and are implicated in the
pathogenesis of diabetes and in its related cardiovascular com-
plications [4, 5]. A number of clinical studies have linked
elevated AGEs in the plasma proteins and skin collagen of
diabetic patients to the risk of vascular complications [6, 7].
In preclinical studies, the pathological role of dicarbonyl
glycation has been demonstrated using pharmacological in-
hibitors, or by altering expression of the dicarbonyl detoxify-
ing enzyme, glyoxalase I (Glo I) [8–10].
As mitochondrial damage due to reactive 1,2-dicarbonyls
contributes to diabetic heart failure, sequestering 1,2-
dicarbonyls within mitochondria before they cause damage
suggests itself as a potential therapy. Previously, we devel-
oped a probe called MitoG to assess the mitochondrial levels
of methylglyoxal and glyoxal [11]. MitoG incorporates a tri-
phenylphosphonium (TPP) moiety that drives the com-
pound’s selective accumulation within mitochondria due to
the membrane potential [11, 12]. MitoG also contains an o-
phenylenediamine moiety that reacts selectively with
methylglyoxal and glyoxal to form stable quinoxaline prod-
ucts that can be quantified by LC-MS/MS [11]. This approach
enabled mitochondrial dicarbonyl levels to be assessed
in vivo. These findings suggested that a mitochondria-
targeted molecule that sequestered 1,2-dicarbonyls might
have therapeutic potential by decreasing mitochondrial dam-
age in diabetic cardiomyopathy. However, because MitoG is
susceptible to oxidation, it was too short lived to be effective
as a therapy. Therefore, we developed a longer-lived ana-
logue, MitoGamide (Fig. 1a). This was done by removing
electron density from the aryl diamine by using an electron
withdrawing amide linkage (Fig. 1a), rather than an electron-
donating ether link as was used inMitoG.MitoGamide should
react with and sequester glyoxal and methylglyoxal to form
the inactive products methylquinoxaline amide (MQA) and
quinoxaline amide (QA) (Fig. 1a). Furthermore, its enhanced
stability is intended to enable MitoGamide to accumulate in
cardiac mitochondria, sequester reactive 1,2-dicarbonyls and
thereby decrease mitochondrial damage and ameliorate dia-
betic cardiomyopathy (Fig. 1b). In a preliminary study,
MitoGamide was protective against diabetic cardiomyopathy
in an Akita mouse model of experimental diabetes [13].
Here, we set out to confirm and extend the results of
MitoGamide in an independent investigation, an important
requirement for the robust validation of cardioprotective
drugs. As preclinical models to assess therapies for HFpEF
are not well developed, we first characterized the cardiomy-
opathy in the Akita mouse model of diabetes. These mice
arose spontaneously from a C57BL6/6NSlc background and
have minimal insulin secretion leading to chronically elevated
plasma glucose [14, 15]. Here, we show that Akita mice de-
velop diabetic pathologies, including HFpEF, and hence can
be used to assess potential therapies. When we treated Akita
mice with MitoGamide, we found that it decreased the devel-
opment of diastolic dysfunction, raising the prospect that
mitochondria-targeted therapies may help in treating diabetic
cardiomyopathy.
Methods
Animal Use and Echocardiography
Wild-type C57BL/6 J (Charles River Laboratories, UK) and
heterozygous Ins2Akita (The Jackson Laboratory, USA) male
mice were used for experiments. Ins2Akita, hereafter called
Akita, carry a single nucleotide substitution in the insulin 2
gene (Ins2). This mutation results in misfolding of proinsulin
2 and eventually leads to ER stress and pancreatic β cell
failure and ultimately to severe hyperglycaemia. At 5 weeks
of age, Akita mice developed hyperglycaemia with non-
fasting blood glucose levels higher than 25 mM. For chronic
MitoGamide treatment, 6-week-old mice were subjected to
daily oral administration via gavage of MitoGamide
(10 mg/kg) or vehicle (sterile water) for 12 weeks. Blood
glucose and HbA1c levels (service provided by Core
Biochemical Assay Laboratory, Cambridge University
Hospital) were monitored during the treatment period.
Cardiac function and morphology were evaluated using echo-
cardiography (Vevo 3100, VisualSonics). The parasternal
long-axis view (B mode), the short-axis view (M mode) and
blood flow velocity (PWmode) at mitral valve were obtained,
and measurements of cardiac structure and function were
accessed using Vevo Lab (VisualSonics) in a completely
blinded manner.
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MitoP/B: Measurement of Mitochondrial Oxidative
Stress In Vivo
As previously described [16], the mitochondria-targeted probe
MitoB reacts with hydrogen peroxide and is converted to
MitoP. The ratio of MitoP/MitoB is used as a quantitative
measurement indicating mitochondrial H2O2 levels. MitoB
(1 μmol/kg) was injected intravenously via tail vein. After
3 h, tissues were collected and snap frozen in liquid N2, sub-
sequently stored at − 80 °C until LC-MS analysis.
ATP/ADP Assay
See supplementary information.




Quantification of MitoGamide, MQA and QA Using LC-
MS/MS
See supplementary information.
Cellular Uptake of MitoGamide
C2C12 myoblasts were maintained in DMEM supplemented
with 10% foetal bovine serum and 1% penicillin/streptomycin
at 37 °C with 5% CO2 in a humidified incubator. Two days
prior to experiment, cells were seeded in a 6-well plate with
normal culture medium. When cells reached 60–70%
confluency, the MitoGamide at various concentrations (0,
10, 50 and 100 nM) was added to each well. After 1 h or
24 h incubation time, cells were collected using cell scrapers
after rinsing with PBS. Cell pellets were collected by centri-
fugation at 16000×g for 3 min. The supernatant was
discarded, and cell pellets were stored at − 80 °C until LC-
MS/MS analysis (see supplementary information).
Mitochondrial Uptake of MitoGamide Using RP-HPLC
Freshly isolated rat heart mitochondria (1-mg protein/ml)
were incubated in 1-ml pre-warmed KCl buffer supplemented
with rotenone (4 μg/ml), internal standard propyl triphenyl-
phosphonium (PTPP; 5 μM) andMitoGamide (5 μM) in 2-ml
microtubes. Respiration was initiated by the addition of suc-
cinate (5mM) with or without FCCP (500 nM). After 5 min of
incubation in a shaking water bath at 37 °C, mitochondria
were pelleted by centrifugation (7500×g for 10 min at 4 °C).
Supernatants (750 μl) were removed and stored at − 80 °C in
microtubes until analysis. Mitochondrial pellets were extract-
ed in 250-μl buffer B (acetonitrile + 0.1% trifluoroacetic acid
(TFA)) followed by centrifugation (7500×g for 5 min). All
samples were diluted to 25% acetonitrile with buffer A (water









GC-MS Analysis of Protein Glycation Markers
Markers of protein glycoxidation (Nε-(carboxyethyl)-lysine
[CEL] , N ε - ( ca rboxymethy l ) - lys ine [CML] , and
S-(carboxymethyl)-cysteine [CMC]) were determined as
trifluoroacetic acid methyl esters (TFAME) derivatives in acid
hydrolyzed delipidated and reduced tissue/mitochondrial pro-
tein samples by GC/MS using a HP6890 Series II gas chro-
matograph (Agilent) with a MSD5973A Series detector and a
7683 Series automatic injector, a HP-5MS column (30 m ×
0.25 mm× 0.25 μm), and the described temperature program
[17, 18]. Quantification was performed by internal and exter-
nal standardization using standard curves constructed from
mixtures of deuterated and non-deuterated standards.
Analyses were carried out by selected ion-monitoring GC/
MS (SIM-GC/MS). The ions used were as follows: lysine
and [2H8]lysine, m/z 180 and 187, respectively; CEL and
[2H4]CEL, m/z 379 and 383, respectively; CML and
[2H2]CML, m/z 392 and 394, respectively; and CMC and
[13C3-
15N]CMC, m/z 271 and 273, respectively. The amounts
of product were expressed as μmoles of CEL, CML or CMC
per mole of lysine.
Statistics
Data are presented as means ± SEM. Comparisons of a single
variable in ≥ 2 groups were analysed by Student’s t test or one-
way ANOVA followed by Tukey’s multiple comparison tests
(GraphPad Prism). Values of p < 0.05 were considered
significant.
825Cardiovasc Drugs Ther (2020) 34:823–834
Results
Akita Mice as a Preclinical Model of Diabetic HFpEF
To validate the protective effects of MitoGamide described
previously, we first independently confirmed the phenotype
of Akita mice. Body weight, blood glucose and HbA1c in
Akita mice were monitored from 6 weeks of age and com-
pared with C57BL6/J wild-type mice (Fig. 2). In agreement
with previous reports [19, 20], Akita mice were smaller and
developed severe hyperglycaemia when compared with wild-
type mice (Fig. 2a–c). Cardiac functional and structural
changes were monitored by echocardiography every 2 weeks
from 12 weeks of age (Fig. 2d–i). At 18 weeks of age, Akita
mice developed diastolic dysfunction, evidenced by a signif-
icantly reduced E peak velocity, reduced E/A ratio (< 1.15)
and extended isovolumetric relaxation time (> 20.0 ms), mea-
sured via mitral valve blood flow (Fig. 2g–i ). Even so, sys-
tolic function, represented by ejection fraction (EF) and cardi-
ac output (CO), was comparable between Akita and wild-type
mice (Fig. 2d–e). Finally, analysis of mRNA expression in
hearts from Akita mice showed an upregulation in expression
of a number of genes associated with heart failure [21], in-
cluding Nppa, Nppb, Gdf15, Fgf21 and Myh7 (Fig. 2j).
Furthermore, Akita mice showed increased relative lung and
liver weights, which has to be seen in light of the reduced
overall weight but might indicate congestive HF-associated
peripheral oedema in Akita mice (Fig. 2k–l). There was no
difference in inflammatory markers between wild-type and
Akita mice (Fig. S3). The combination of diastolic dysfunc-
tion with preserved systolic function replicates some of the
clinical features of early-stage diabetic cardiomyopathy in
humans [1].
We next analysed mitochondrial function in Akita mice at
16 weeks of age (Fig. 3a–d). The cardiac ATP/ADP ratio of
Akita mice was ~ 30% lower than for wild-type mice (Fig. 3a).
Mitochondrial H2O2 levels in vivo, measured using the
mitochondria-targeted MitoB probe [16], showed higher hy-
drogen peroxide levels in the cardiac mitochondria of Akita
mice compared with controls (Fig. 3b). Transmission electron
micrographs (TEM) of cardiac tissue showed disruption in
mitochondrial morphology in Akita mice, compared with wild
type (Fig. 3c). Quantification of electron micrographs indicat-
































































Fig. 1 Activity of MitoGamide. a
The reactions of MitoGamide
with glyoxal to form quinoxaline
amide (QA) and methylglyoxal to
form methylquinoxaline amide
(MQA: note that there are two
regioisomers of MQA). b
Schematic showing the effect of
elevated glucose on mitochondri-
al dysfunction leading to diabetic
cardiomyopathy and its preven-
tion by MitoGamide
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shown), but that there was an increase in mitochondrial den-
sity (Fig. 3d). We conclude that Akita mice develop heart
dysfunction similar to that found in HFpEF patients and that
this pathology is associated with mitochondrial dysfunction.
Importantly, we also showed that this cardiac phenotype is
conserved as these results mirror the previous study, despite
being carried out at independent centres.
In Vitro Properties of MitoGamide
The findings described above are consistent with elevated
glucose leading to mitochondrial dysfunction and cardiomy-
opathy in Akita mice. A plausible pathway contributing to
mitochondrial dysfunction is through glycation of mitochon-
drial proteins by the elevated 1,2-dicarbonyls that arise as a
Fig. 2 Comparison between wild-type and Akita mice in a body weight
(n = 11–15), b non-fasting blood glucose levels (n = 11–15) and c plasma
HbA1c levels (n = 4–6). Longitudinal echocardiographic analysis of
Akita and wild-type hearts was used to measure left ventricular (LV)
ejection fraction (EF) (d), cardiac output (CO) (e), LV mass (f), E peak
(g), E/A ratio (h) and isovolumetric relaxation time (IVRT) (i).Values are
expressed as mean ± SEM (n = 11–15). (j) shows mRNA expression of
biomarkers of heart failure in heart tissues (n = 4–6); Lgals3 galectin-3,
Nppa natriuretic peptide-A, Nppb natriuretic peptide-B, Gdf15 growth
differentiation factor 15, Fgf21 fibroblast growth factor 21,Myh7myosin
heavy chain 7. (k-l) show the difference between wild-type and Akita
mice in lung and liver weights (mg), normalized by body weight (g).
Statistical significance has been tested with Student’s t test
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consequence of high glucose levels in the Akita mice.
Therefore, we generated a mitochondria-targeted compound,
MitoGamide (Fig. S1), that accumulates within mitochondria
and sequesters the damaging 1,2-dicarbonyls that contribute
to mitochondrial damage and heart dysfunction (Fig. 1b).
MitoGamide was based on MitoG [11], but altered to in-
corporate an electron withdrawing amide linker between the
mitochondria-targeting TPP moiety and the dicarbonyl se-
questering phenylenediamine moieties (Fig. S1). This was
done to decrease oxidation of the phenylenediamine so as to
extend MitoGamide’s lifetime in vivo while still sequestering
1,2-dicarbonyls. The synthesis of MitoGamide and related
compounds are shown in Fig. S1.
The UV absorption spectrum and the RP-HPLC analysis of
MitoGamide and its products from reaction with glyoxal (QA)
and methylglyoxal (MQA) are shown in Fig. 4a and b. RP-
HPLC analysis of MitoGamide following reaction with
methylglyoxal (Fig. 4c) or glyoxal (Fig. 4d) showed that
MitoGamide reacted with 1,2-dicarbonyls to form the expected
products, MQA and QA, respectively. MitoGamide accumulat-
ed ~ 500-fold within energized mitochondria, and this accumu-
lation was prevented by abolishing the mitochondrial mem-
brane potential with the uncoupler FCCP (Fig. 4g).
MitoGamide was also taken up into C2C12 myoblasts in a
dose-dependent manner (Fig. 4e). The MitoGamide uptake
was unchanged from 1 to 24 h, indicating that a stable steady-
state distribution was rapidly established and that MitoGamide
was stable within cells. Incubation with MitoGamide led to the
accumulation of MQA, the reaction product of MitoGamide
with methylglyoxal (Fig. 4f), indicating thatMitoGamide reacts
with the methylglyoxal generated spontaneously during glu-
cose metabolism. In contrast, there was a negligible accumula-
tion of QA, the product from the reaction of MitoGamide with
glyoxal (data not shown). Treating C2C12 cells with exoge-
nous methylglyoxal or glyoxal led to ~ 50% loss of viability
(Fig. 4h). MitoGamide showed a dose-dependent protection
against methylglyoxal toxicity (Fig. 4h). MitoGamide was less
protective against glyoxal, probably due to the greater reactivity
of methylglyoxal with MitoGamide. This arises because
methylglyoxal is mostly present as the monohydrate that re-
quires a single dehydration to generate the reactive dicarbonyl,
whereas glyoxal is a dihydrate making it less reactive.
Together, these data indicate that MitoGamide is taken up
by mitochondria and cells, where it is stable and reacts with
methylglyoxal, thereby protecting against the damage caused
by 1,2-dicarbonyls.
Glycation Endproducts in Akita Mice
Reactive dicarbonyls such as methylglyoxal and glyoxal are
thought to react primarily with lysine, arginine and cysteine
residues in proteins [17, 18, 22]. The resulting adducts include
Nε-(carboxymethyl)-lysine (CML), Nε-(carboxyethyl)-lysine
(CEL) and S-(carboxymethyl)-cysteine (CMC) [16, 17]
(Fig. 5a). To extend our knowledge on the Akita mouse model
and its phenotype, we measured these adducts by GC-MS in
tissues from wild-type and Akita mice (Fig. 5b–f).
Unexpectedly, the liver, kidney, plasma and heart from
Fig. 3 Mitochondrial function in
Akita mice. a Measurement of
ATP/ADP ratio in the myocardial
tissue of Akita and wild-typemice
(n = 4–7). b Measurement of mi-
tochondrial hydrogen peroxide
levels assessed by measuring
MitoP/B ratio using LC-MS/MS
(n = 10). c Representative TEM
images of heart tissues from wild-
type and Akita heart tissues. d
Quantification of mitochondrial
density in cardiomyocytes
accessed by TEM. Values are
expressed as mean ± SEM, and
statistical significance has been
tested with Student’s t test
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Fig. 4 In vitro characterization of MitoGamide. aUV/Vis scanning spec-
tra of 100 μM MitoGamide, MQA and QA in KCl buffer. b RP-HPLC
profile of 10-nmolMitoGamide, MQA and QAmade up fresh in DMSO.
Absorbance wasmeasured at 220 nm. c,dReactionmixtures consisting of
5-mM MitoGamide and 10-mM methylglyoxal or glyoxal in a final vol-
ume of 10 μl in KCl buffer A were incubated at 37 °C for 2 h. For RP-
HPLC, 1 μl of each mixture was used. e,fDose-dependent cellular uptake
level of MitoGamide and time-dependent accumulation of MQA in
C2C12 cells, measured by LC-MS/MS (n = 3–6). Values are mean ±
SEM. g MitoGamide accumulation by isolated rat liver mitochondria,
measured by HPLC (n = 3). h Effect of MitoGamide at various doses in
C2C12 cell viability accessed by MTT assay when cells were exposed to
exogenously added methylglyoxal or glyoxal (1 mM) (n = 4). The effects
of MitoGamide treatment have been tested by one-way ANOVA
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Akita mice did not show increased levels of these adducts
compared with wild-type mice (Fig. 5b–e). To see whether
these adducts might be enriched in the mitochondria, we
assessed heart mitochondria by GC-MS (Fig. 5f) and by
Western blotting using an antibody selective for the
methylglyoxal-modified arginine adduct argpyrimidine (Fig.
5g). However, there was again no difference in adduct forma-
tion between wild-type and Akita mice.
We next considered whether the lack of increased protein
glycation in Akita mice, despite elevated glucose, was due to a
compensatory upregulation of defences against protein
glycation. The major enzyme responsible for methylglyoxal
Fig. 5 a Structures of CEL, CML and CMC. b–e Tissue accumulation of
methylglyoxal or glyoxal-mediated AGEs, CEL, CML and CMC were
accessed using GC-MS in wild-type and Akita mice (12–15 weeks old)
(n = 8–11). f,g Data representing the AGE levels in mitochondrial
fractions of heart tissues from wild-type or Akita mice, assessed by f
GC-MS (n = 5) and g Western blot analysis. h Representative Western
blot comparing glyoxalase I protein expression and activity between
wild-type and Akita (n = 4)
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and glyoxal detoxification is glyoxalase I (Glo I) [5, 8, 23].
However, Akita mice did not upregulate Glo I expression or
activity (Fig. 5h).
MitoGamide Distribution In Vivo
To see if MitoGamide could be effective as a potential thera-
peutic, we next assessed its distribution to target tissues
in vivo. To do this, we first developed an LC-MS/MS assay
for MitoGamide, MQA and QA (Fig. S2) that enabled us to
measure their levels in tissues. We assessed the tissue distribu-
tion of MitoGamide 4 h after intravenous injection (Fig. 6a–c),
which showed a significant MitoGamide uptake into the heart.
Interestingly, there were higher levels of MitoGamide in the
hearts of Akita mice compared with wild-type mice, possibly
due to the increased mitochondrial density in the
cardiomyocytes of Akita mice, as reported previously [19]
and confirmed by our own TEM analysis (Fig. 3c).
Significant amounts of MitoGamide were also detected in the
kidney (Fig. 6b) and liver (Fig. 6c) of wild-type and Akita
mice. Both MQA and QA were detected in spot urine samples
from both wild-type and Akita mice following MitoGamide
injection (Fig. S4). Thus, MitoGamide is taken up from the
circulation into tissues and there reacts with methylglyoxal
and glyoxal. As intravenous injection is not feasible for a clin-
ically relevant long-term MitoGamide administration, we next
assessed tissue distribution following administering
MitoGamide by oral administration via intragastric gavage
(Fig. 6d–f). This showed that there were reasonable amounts
of MitoGamide present in the heart (Fig. 6d) and liver (Fig. 6f)
for several hours after gavage, while in the kidney,
MitoGamide was cleared relatively rapidly (Fig. 6e).
Therefore, MitoGamide is taken up into the heart, is reasonably
stable and reacts with methylglyoxal and glyoxal in vivo.
MitoGamide Protects Against Cardiac Dysfunction in
Akita Mice
To confirm whether MitoGamide could protect against diabet-
ic cardiomyopathy, we treated Akita mice with MitoGamide
daily for 12 weeks by oral gavage and assessed a range of
markers of heart function by echocardiography (see
Supplementary Table S1). MitoGamide treatment significant-
ly improved the E/A ratio (Fig. 6g). Importantly, the E/A ratio
is a key indicator of diastolic dysfunction in the development
of diabetes-inducedHFpEF in patients [24]. This suggests that
MitoGamide counteracts some of the damaging consequences
of diabetes that lead to diastolic cardiac dysfunction.
MitoGamide did not change body weight, blood glucose or
HbA1c in either Akita or wild-type mice (data not shown).
This protection against cardiac dysfunction was the same as
that seen in the previous study, validating the effectiveness of
MitoGamide [13] and following recent guidelines [25].
MitoGamide can intercept reactive 1,2-dicarbonyls and
thereby prevent damage (Fig. 4h). However, as there was no
increase in markers of protein glycation in the Akita mice
compared with controls, it was not possible to assess whether
this was how MitoGamide protected against the cardiac dys-
function. Therefore, we assessed the effect of MitoGamide on
other indicators of mitochondrial function (Fig. S5a–e).
However, we found thatMitoGamide did not act by preventing
deleterious mitochondrial changes in Akita mice, including
ATP/ADP ratio (Fig. S5a), mitochondrial ROS levels (Fig.
S5b), expression of genes associated with cardiac dysfunction
(Fig. S5c), nor the increase in mitochondrial density (Fig. S5d).
In addition, MitoGamide did not affect the levels of mitochon-
drial DNA damage in Akita mice (Fig. S5e). However, there
was an increase in mitochondrial levels of LC3B II and Pink1
in the hearts of Akita mice compared with wild type (Fig. S6a–
d), suggesting that Akita mice might upregulate autophagy to
adapt to the metabolic changes in the tissue. MitoGamide treat-
ment only reduced LC3B II, while others stayed unaffected;
hence, further investigation is needed to fully understand the
role of autophagy in the observed protection.
Discussion
Diabetes is a highly prevalent risk factor in the development of
HFpEF, and diabetic HFpEF patients have a marked increase in
morbidity and mortality. HFpEF is a complex clinical syn-
drome which is mainly, but not exclusively, characterized by
diastolic cardiac dysfunction, a systemic pro-inflammatory
state, and a preserved or only mildly impaired systolic cardiac
pump function. HFpEF is now regarded as one of the main
forms of chronic heart failure with an increasing prevalence
worldwide [26]. In contrast to heart failure with reduced ejec-
tion fraction (HFrEF), there are currently no specific therapies
for HFpEF. One of the reasons for the failure to develop and test
specific HFpEF therapies lies in the lack of suitable preclinical
animal models. Here, we have shown that the Akita mouse
model of type I diabetes replicates many features of HFpEF,
in particular cardiac diastolic dysfunction, making it a potential
model to assist in the development of new drugs for this dis-
ease. In addition, the development of cardiac phenotypes that
replicate those of HFpEF in Akita mice was associated with
mitochondrial dysfunction. Mitochondrial dysfunction is con-
sidered to be a direct consequence of the systemic pro-
inflammatory conditions found in HFpEF, aggravated by a di-
abetic environment [27, 28]. Although we could not find any
changes in the systemic inflammatory state of Akita mice, they
showed increased oxidative stress seen by increased mitochon-
drial H2O2 production in vivo. Akita mice might develop com-
pensatory mechanisms to counteract chronic inflammation,
which will be investigated in future work.
831Cardiovasc Drugs Ther (2020) 34:823–834
Taken together, in accordance with previous studies [15,
19, 20], the Akita mouse model demonstrated several patho-
gnomonic features of HFpEF, rendering it suitable to test nov-
el treatment options. As the formation of reactive 1,2-
dicarbonyls such as glyoxal and methylglyoxal is associated
with elevated levels of glucose, we hypothesised that
glycation of mitochondrial proteins by these reactive
dicarbonyls was a major cause of the mitochondrial dysfunc-
tion and cardiac damage in the Akita mice. Hence, we devel-
oped a mitochondria-targeted compound, MitoGamide, de-
signed to sequester reactive dicarbonyls. MitoGamide was
protective against diastolic dysfunction, one of the major
HFpEF components in these mice. Although we hypothesised
that MitoGamide protects cells against dicarbonyl damage, it
was difficult to assess this mechanism directly in vivo, as there
was no elevation of protein glycation in the Akita mice com-
pared with wild-type mice. The lack of accumulation of pro-
tein adducts was surprising, given that the elevated glucose in
the Akita mice leads to increased amounts of methylglyoxal
and glyoxal. This was not due to an upregulation of glyoxalase
I activity; however, we cannot exclude the possibility that the
Akita mice have developed alternative compensatory mecha-
nisms to adapt to the dicarbonyl stress associated with
hyperglycaemia. Furthermore, we could not see changes in
the expression of key heart failure-associated genes (Fig.
S5c), which could indicate that despite MitoGamide improv-
ing diastolic dysfunction, there is an ongoing drive from the
diabetic state of these mice towards heart failure development.
The present study is not providing a clear molecular mecha-
nism of action supporting the cardioprotective effect seen in
MitoGamide-treated Akita mice. Diabetic complications
in vivo are multi-factorial and often secondary to changes in
other AGE-sensitive organs. Therefore, effects on the heart
cannot be fully distinguished from effects of MitoGamide in
other areas which we have not examined. Indeed, in addition
to hyperglycaemia and insulin deficiency, Akita mice are
Fig. 6 Tissue distribution and in vivo effect of MitoGamide in mice. a–c
MitoGamide level was measured in tissues, heart, kidney and liver,
collected 4-h post i.v. injection (100-nmol/mouse, or equivalent to
2 mg/kg for mice weighing 25–30 g) from both wild-type and Akita mice
(n = 5). The difference between wild-type and Akita groups has been
tested with Student’s t test. d–f MitoGamide (10 mg/kg, approximately
500 nmol/mouse) was given to mice by oral gavage; then its contents in
heart, liver and kidney were measured by LC-MS/MS (n = 3). Values are
mean ± SEM. Effect of MitoGamide on heart function. g The effect of
12 week long MitoGamide treatment (10 mg/kg daily oral gavage) on E/
A ratio, accessed by echocardiography (n = 11–15). h Representative
Western blot and the quantification of LC3II expression normalized by
LC3I in mitochondrial fractions of heart tissues collected after the
12 weeks treatment (n = 3–6). Values are mean ± SEM. Statistical signif-
icance has been tested by One-way ANOVA
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prone to develop retinopathy, nephropathy, atherosclerosis,
dyslipidaemia and a higher expression of pro-inflammatory
factors [14, 29]. The influence of these changes on the cardiac
pathologies and MitoGamide’s protection still warrants fur-
ther work.
In conclusion, we have demonstrated that the Akita mouse
model replicates many cardiac phenotypes observed in
diabetes-associated HFpEF at both physiological and molec-
ular levels. Furthermore, the robust protection afforded by
MitoGamide, in multiple independent studies, against cardiac
myopathy in this model suggests that mitochondria-targeted
therapies may be of utility in addressing cardiac dysfunction
associated with diabetes. However, the lack of AGE accumu-
lation in Akita mice made it impossible to fully elucidate the
in vivo effect of MitoGamide and is also not in line with
clinical results showing elevated AGE levels in tissue and
plasma of diabetic patients. Moreover, other well-established
diabetes mouse models such as db/db and high-fat/high-su-
crose fed mice have not shown clear evidence of AGE accu-
mulation at the age range which various diabetic phenotypes
are detected [30]. This leaves us with a challenge to find a
suitable preclinical animal model closely matching with the
clinical pathogenesis to test novel therapeutic compounds
such as MitoGamide.
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